Piramal Pharma Solutions Enhances HPAPI Manufacturing with New Korsch X3 Tablet Press
Morpeth, UK – Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO), has installed a Korsch X3 high-containment tablet press at its facility in Morpeth, UK. This investment coincides with the 20th anniversary of the Morpeth site and expands the company’s capacity for manufacturing highly potent active pharmaceutical ingredients (HPAPIs) for both clinical and commercial use.
Expanding Capabilities for Complex Therapies
The Korsch X3 is a state-of-the-art tablet press custom-built to meet the specific needs of the Morpeth facility. Equipped with full Band 5 containment and a specialized DryCon containment kit, the press enables the safe and contained manufacture of highly potent drug products. This positions Piramal Pharma Solutions to meet the increasing demand for complex therapies requiring stringent safety protocols.
Key Features of the Korsch X3
The new tablet press offers several key advantages:
- High Containment: The Band 5 containment system ensures operator safety when handling potent compounds.
- Tablet Size Versatility: Two customized turrets support the manufacture of tablets up to 25mm in size, expanding the range of formulations that can be produced.
- Efficient Material Handling: Contained infeed from tote bins via split butterfly valve transitions and a finished product chute that transfers tablets directly to coating operations streamline the manufacturing process.
- Dust Control: A misting system manages residual dust following batch completion, further enhancing safety and cleanliness.
Building on a Strong Foundation
The installation of the Korsch X3 follows the earlier commissioning of a Korsch XM12 single layer/bilayer tablet press at the Morpeth site. As demand increased for late-phase and commercial programs, the need for equipment capable of handling a wider range of tablet sizes became apparent. The Korsch X3 was selected based on a long-standing relationship between Piramal Pharma Solutions and Korsch, a respected brand in the pharmaceutical industry.
Commitment to Innovation and Safety
“By expanding Morpeth’s ability to manufacture tablets containing Band 5 HPAPI, the Korsch X3 is the ideal way to celebrate the facility’s 20th anniversary, reinforcing its legacy of helping to improve and prolong the lives of patients around the world,” said Peter DeYoung, CEO of Piramal Global Pharma.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering comprehensive solutions across the drug lifecycle. PPS operates a globally integrated network of facilities in North America, Europe, and Asia, providing services including drug discovery, pharmaceutical development, clinical trial supplies, and commercial manufacturing of APIs and finished dosage forms. PPS also specializes in high-potency APIs, antibody-drug conjugations, sterile fill and finish, peptide products, and potent oral solid drugs.
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) offers a diversified portfolio of products and services through 17 global development and manufacturing centers and a distribution network in over 100 countries. PPL encompasses Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and Piramal Consumer Healthcare. The company also holds strategic investments in Yapan Bio Private Limited and Abbvie Therapeutics India Private Limited.